Eskulap Pabianice Sp. z o.o.
- Address
- Ul. Grobelna 8, 95-200 Pabianice, Poland
Eskulap Pabianice Sp. z o.o.
Eskulap Pabianice is a clinical research facility specializing in gastroenterological and endocrine disorders. The center demonstrates expertise in conducting Phase II and Phase III clinical trials evaluating novel therapeutic interventions for inflammatory bowel diseases and rare autoimmune conditions affecting endocrine organs.
- Ulcerative colitis clinical remission studies with emerging biological therapies
- Thyroid eye disease (TED) research encompassing both active and chronic disease phases
- Subcutaneous biologics administration and tolerability assessment
The center has particular strength in evaluating novel immunomodulatory agents for autoimmune conditions. Their research portfolio includes assessment of efficacy endpoints such as clinical remission in ulcerative colitis and symptomatic improvement in thyroid eye disease, with extensive experience in both active and chronic disease management protocols. The facility's expertise extends to safety and tolerability evaluation of investigational products administered through various routes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1F. Hoffmann-La Roche AG3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Eskulap Pabianice Sp. z o.o.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study of Afimkibart Effects on Cytochrome P450-Mediated Drug Metabolism in Patients With Active Ulcerative Colitis | F. Hoffmann-La Roche AG | Phase I | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| VRDN-003 | 2 | Unknown | 2025-02-25 | 2025-02-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.